Cardiac Injury Due to Anthracycline in Paediatric Oncological Patients

NCT06898320 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 22

Last updated 2025-05-09

No results posted yet for this study

Summary

The study investigates the role of echocardiography and of serum biomarkers (NT-proBNP, cardiac Troponin-I) in predicting cardiac injury in a cohort of paediatric oncological patients treated with Anthracycline chemotherapy.

Conditions

  • Heart Injuries
  • Anthracycline

Sponsors & Collaborators

  • IRCCS Burlo Garofolo

    lead OTHER

Principal Investigators

  • Thomas Caiffa, MD · IRCCS Burlo Garofolo

Eligibility

Min Age
0 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-21
Primary Completion
2033-07-21
Completion
2033-07-21

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06898320 on ClinicalTrials.gov